Global End-Stage Renal Disease (ESRD) Market Size, Share, Growth Analysis, By Treatment (Dialysis, Kidney and Transplantation), By End-user (Hospitals and Clinics, and Home Care Settings) - Industry Forecast 2023-2030

Global End-Stage Renal Disease Market (ESRD) size was valued at USD 8.8 billion in 2021 and is poised to grow from USD 99.2 billion in 2022 to USD 234.82 billion by 2030, growing at a CAGR of 13.1% during the forecast period (2023-2030).

The expanding prevalence of kidney failure, propelled by factors like Chronic Kidney Disease (CKD) resulting from conditions leading to diminished kidney function, has driven the demand for advanced medical solutions. The market is witnessing a surge due to the growing number of individuals afflicted with CKD, and the introduction of sophisticated medical devices such as low-maintenance dialysis equipment and artificial kidneys. CKD often progresses to End-Stage Renal Disease (ESRD), with hypertension, diabetes, smoking, and an aging population contributing to its development. CKD's global incidence is high, affecting around 10% of the world's population and causing millions of deaths annually. The geriatric populations in countries like China and India are particularly affected. Treatment options, including kidney transplantation and dialysis, play a crucial role in sustaining life for ESRD/CKD patients. Diabetes, affecting approximately 1 billion people worldwide, is the primary cause of advanced kidney disease. The market is witnessing substantial growth, driven by factors like the rising number of individuals with hypertension and diabetes, especially among women. Notably, strategic initiatives by major companies, such as Baxter, contribute to the market's evolution. Various regions, including Africa, China, the U.S., and several European countries, have seen a notable increase in ESRD cases. In the U.S., CKD is a significant health risk, with around 80 million people at risk and 1 in 3 adults affected. Developing countries like China and India are projected to experience a rise in renal failure cases, particularly among the elderly. Technological advancements, exemplified by innovations like the Wearable Artificial Kidney 2.0, approved for human clinical trials by the U.S. FDA in 2014, further drive market growth. The presence of well-established healthcare infrastructure in the U.S., along with a growing number of hospitals, dialysis clinics, and treatment centers, contributes to the increasing demand for renal failure treatments.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global End-Stage Renal Disease Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global End-Stage Renal Disease Market Segmental Analysis

The Global End-Stage Renal Disease Market is segmented by treatment, end-user, technique and region. Based on Treatment, the market can be segmented into dialysis, kidney and transplantation. Based on end-user, the market is segmented into hospitals and clinics, and home care settings. Based on region, the market is segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.

Drivers of the Global End-Stage Renal Disease Market

The rising occurrence of chronic kidney disease (CKD), notably influenced by conditions like hypertension and diabetes, is a prominent factor fueling the global end-stage renal disease market. As a substantial number of individuals worldwide grapple with these chronic ailments, the likelihood of developing CKD and advancing to end-stage renal disease (ESRD) increases. This expanding patient demographic underscores the imperative need for efficient treatment solutions, encompassing kidney transplantation or dialysis, consequently driving the market's expansion.

Restraints in the Global End-Stage Renal Disease Market

A significant obstacle in the worldwide end-stage renal disease market is the restricted availability and accessibility of treatment alternatives, notably kidney transplantation. The demand for kidney transplants surpasses the supply of suitable organs, resulting in prolonged waiting lists and delays in transplant procedures. Furthermore, although dialysis is a viable treatment, issues related to patient compliance, cost, and the necessity for regular sessions present challenges. These constraints serve as barriers to providing timely and optimal treatment for individuals grappling with end-stage renal disease, thereby impeding market growth.

Market Trends of the Global End-Stage Renal Disease Market

A prominent trend in the global end-stage renal disease (ESRD) market is the rising preference for home-based dialysis treatments, fueled by the aim to enhance patient convenience, lower healthcare costs, and improve patient outcomes. Therapies like peritoneal dialysis and home hemodialysis provide increased flexibility, independence, and the convenience of receiving treatment in the familiar surroundings of one's home. The transition to home-based dialysis is backed by technological advancements, enhanced training programs, and favorable reimbursement policies, contributing significantly to the market's expansion.